According to BBX data, the first public collapse case in the corporate digital asset reserve sector occurred yesterday, and on the same day, the crypto industry jointly issued the largest legislative mobilization of the year. Several listed companies disclosed their latest reserve actions, with the core dynamics as follows:
Satsuma Technology Plc (LSE: $SATS) reported by Bloomberg on April 23 that digital asset investment firm Pantera Capital (holding approximately 6.7%) is pressuring the company, along with other shareholders, to liquidate all 646 BTC (current market value approximately $50 million) and return the cash to shareholders. The company's executive chairman, Ranald McGregor-Smith, confirmed that they have received requests from shareholders for capital return, stating that they are "evaluating options."
DeFi Development Corp. (NASDAQ: $DFDV) announced that its Treasury Accelerator Program has completed a strategic equity investment in Japanese listed company Allied Architects, Inc. (TSE: 6081), marking the company's first entry into the Asian market. As of recently, the company holds approximately 2.2 million SOL (market value approximately $195 million), using "SOL per Share (SPS)" as a core performance indicator.
H100 Group AB (OTCMKTS: $HOGPF) upgraded the letter of intent (LOI) signed in March to a binding share purchase agreement, intending to acquire a total of approximately 2,450 BTC reserves from Moonshot AS and Never Say Die AS; upon completion, the company's BTC holdings are expected to rise to approximately 3,501 BTC, with the transaction structure being all-stock consideration (BTC for BTC, no cash involved). Existing shareholders are expected to hold about 30% after completion, with the delivery expected to be completed by August 2026.
Remixpoint, Inc. (TSE: 3825) recently increased its holdings by 20.0312 BTC (approximately $1.57 million), bringing its total BTC holdings to 1,431.33 BTC, with a current paper profit of approximately $21.28 million; the company also plans to purchase approximately $3.13 million in additional crypto assets.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.













Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.